Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring: A Reasoned Evaluation of Risk.

This review looked at whether taking paracetamol during pregnancy increases autism and ADHD risk. While some studies found tiny increases in risk, when researchers compared siblings (where one was exposed and one wasn't), there was no difference. The actual risk increase is very small - less than 0.1%. Other pain medicines showed similar tiny increases, suggesting the underlying pain or other factors might be responsible, not the medicine itself.

Paracetamol remains one of the safest pain relief options during pregnancy.

This review critically examines claims that maternal acetaminophen (paracetamol) use during pregnancy increases autism and ADHD risk. While two large population studies found small increased risks (hazard ratios 1.05-1.07), sibling analyses showed no association, suggesting genetic/environmental factors rather than drug exposure explain the findings. Similar small risks were found for other pain medications including aspirin and opioids. The absolute risk increase is minimal (0.09% for autism by age 10).

The review emphasizes acetaminophen's superior safety profile compared to alternatives and argues that unmeasured confounding factors likely explain observed associations. Authors advocate for balanced, guilt-free discussions with pregnant women about pain management options.

Acetaminophen remains a safe first-line analgesic during pregnancy. Risk-benefit discussions should emphasize minimal absolute risk increases and superior safety profile compared to alternatives. Avoiding effective pain management may pose greater risks than continued acetaminophen use when clinically indicated.

Review nature limits direct data analysis. Observational studies cannot establish causation. Multiple unmeasured confounding factors may explain associations. Limited discussion of study methodological quality variations.

The US Administration has moved to declare gestational exposure to acetaminophen (paracetamol) a risk factor for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children. This article examines the science on the subject. Studies suggest that about half of women use acetaminophen during pregnancy; nevertheless, there is no epidemic of neurodevelopmental disorders (NDDs) in offspring. Two large population-based studies, one Swedish and the other Japanese, found that maternal use of acetaminophen during pregnancy was associated with an increased risk of ASD, ADHD, and intellectual disability (ID) in children.

However, the risks were very small in fully adjusted analyses; hazard ratios (HRs) were mostly in the 1.05-1.07 range. Importantly, maternal use of aspirin, other NSAIDs, opioids, or antimigraine drugs during pregnancy was also associated with an increased risk of ASD and ADHD (but not ID). Most importantly, in sibling analyses, gestational exposure to acetaminophen, aspirin, and other analgesic drug categories was not associated with an increased risk of NDDs. There are many key points.

Acetaminophen has a safety profile that is better than that of alternative treatments. The magnitude of increase in absolute risk for NDDs is very small (eg, by 0.09% at age 10, for ASD). There are many unmeasured confounds that, evenif weak, could nullify the relationship between acetaminophen and NDDs. Sibling analyses suggest that shared genetic and shared environment risk factors (rather than acetaminophen exposure) may explain the NDD risk.

Analyses of other analgesic drug groups suggest that pain and inflammation, rather than drug exposure, may also explain the NDD risk. Finally, for reasons that are explained, making acetaminophen unavailable during pregnancy does not mean that the NDD risk will reduce. These points need to be discussed with women in a shared decision-making process that is both equitable and free from guilting.